The global Dx AMR collaborative: an approach to strengthen the role of diagnostics in combating antimicrobial resistance

Antimicrobial resistance (AMR) is an escalating global health threat, with deaths linked to AMR projected to rise sharply from nearly 5 million in 2019 to more than 8 million by 2050. Despite this growing risk, international funding for AMR is declining, exemplified by the UK government’s 2025 decision to end support for the Fleming Fund, a key programme supporting surveillance and capacity building in low- and middle-income countries (LMICs). These funding cuts weaken global biosecurity and disproportionately affect countries with the least resources. In response, international organisations are calling for more sustainable and equitable global partnerships, particularly to improve access to diagnostics. To address this gap, the Fleming Initiative coordinated the launch of the WHO-endorsed Dx AMR Collaborative in Ghana in June 2025. Bringing together more than 90 stakeholders worldwide, the initiative aims to accelerate innovation, align investments, and support countries in scaling up the use of diagnostics as a core pillar in the fight against AMR, under the leadership and endorsement of the World Health Organization.